Pain & neurology
Chronic pain, neuropathic pain, musculoskeletal conditions and non-opioid or interventional research supported by the MyPainDr referral pathway.
Independent clinical research site
Valens Clinical Research supports sponsor and CRO studies in pain, psychiatry, cognitive disorders, metabolic health and healthy aging—backed by connected clinical pathways, infusion capability and secure participant intake.
Sponsor inquiries: contact@valensclinicalresearch.com · 202-600-5683
Therapeutic focus
Clinical services and research remain operationally and ethically distinct. With authorization, the network can support outreach and referral; research eligibility, consent and study procedures follow the approved protocol.
Chronic pain, neuropathic pain, musculoskeletal conditions and non-opioid or interventional research supported by the MyPainDr referral pathway.
Major depression, treatment-resistant depression, anxiety, PTSD and substance-use disorders, with eligibility-based coordination through KetamineHubs.
Obesity, cardiometabolic risk, body composition, functional aging and prevention-related studies supported by Valens longevity services.
Mild cognitive impairment, Alzheimer’s disease, agitation and related caregiver-informed research pathways.
Investigational-product administration, monitored observation and protocol-directed procedures supported by trained clinical staff.
Community outreach and connected-service referrals for prescreening, enrollment and retention across approved protocols.
For sponsors and CROs
VALENS can evaluate opportunities against population access, clinical capability, staffing, facility requirements and competing studies before making enrollment commitments.
Site capabilities
Operational model
VALENS evaluates each opportunity against the protocol, population, staffing, facility, equipment and competing-study requirements before committing to enrollment.
Participant rights
Potential participants receive study-specific information about purpose, procedures, foreseeable risks, possible benefits, alternatives, costs, compensation, confidentiality and whom to contact. They may ask questions and may decline or withdraw without losing access to ordinary clinical services.
Registry submission and prescreening are not study enrollment. Eligibility is determined only through the approved study process.
Participants should report health changes, side effects and medication changes and follow protocol instructions.
Investigational procedures may not provide personal benefit and are not a substitute for established treatment unless the protocol specifically provides it.
Industry connection directory
These links identify potential collaboration targets and public research resources. Listing does not represent an existing partnership, endorsement or active VALENS study.
For participants
Joining the registry is not consent to a study and does not guarantee eligibility. If a potentially suitable IRB-approved study is available, research staff will explain the purpose, visits, risks, alternatives, costs and compensation before you decide.
Join secure registryResearch participation is voluntary and separate from private-pay care. Declining or leaving a study does not affect access to clinical services.
Only active studies with appropriate IRB approval may enroll participants. Each study uses its own approved consent form; general website or treatment consents do not replace it.
Protected health information is handled through authorized systems and role-based workflows. Emergency concerns should be directed to 911, not the research registry.
Research education
Send the protocol synopsis, indication, phase, target population, expected start date and major facility requirements for an initial capability review.